Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Receivables (2017 - 2021)

Protagonist Therapeutics' Receivables history spans 5 years, with the latest figure at $1.6 million for Q4 2021.

  • For Q4 2021, Receivables fell 35.45% year-over-year to $1.6 million; the TTM value through Dec 2021 reached $1.6 million, down 35.45%, while the annual FY2021 figure was $1.6 million, 35.45% down from the prior year.
  • Receivables for Q4 2021 was $1.6 million at Protagonist Therapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Receivables topped out at $7.1 million in Q2 2021 and bottomed at $19000.0 in Q2 2017.
  • The 5-year median for Receivables is $2.8 million (2018), against an average of $2.9 million.
  • The largest annual shift saw Receivables skyrocketed 30684.21% in 2018 before it crashed 66.23% in 2019.
  • A 5-year view of Receivables shows it stood at $1.9 million in 2017, then soared by 52.29% to $2.9 million in 2018, then plummeted by 61.46% to $1.1 million in 2019, then skyrocketed by 120.55% to $2.4 million in 2020, then plummeted by 35.45% to $1.6 million in 2021.
  • Per Business Quant, the three most recent readings for PTGX's Receivables are $1.6 million (Q4 2021), $2.6 million (Q3 2021), and $7.1 million (Q2 2021).